Rattandeep Batra

Durable Inhibition of Structural Damage Progression and Improvements in Joint Disease Activity with Guselkumab in Active and Erosive Psoriatic Arthritis: Week 48 Results from Apex

Proton Rahman, Christopher Ritchlin, Philip Mease, Laura Coates et autres

Objectives APEX ( NCT04882098 ) evaluates guselkumab (GUS), a fully human mAb able to bind CD64 and selectively inhibit the IL-23p19-subunit, in participants (pts) with active and erosive PsA. At Week(W)24, GUS demonstrated significantly higher ACR20 rates (primary endpoint) and radiographic progression …

ca, us, gb, be, nl (code pays fourni par la source)

204 Inhibition of Structural Damage Progression With Guselkumab, a Selective IL-23i, in Participants With Active PsA: Results Through Week 24 of the Phase 3b APEX Study

Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier et autres

us, gb, ca, nl (code pays fourni par la source)

331 Durable Inhibition of Structural Damage Progression and Improvements in Joint Disease Activity With Guselkumab in Active and Erosive Psoriatic Arthritis: Week 48 Results From APEX

Christopher T. Ritchlin, Philip J. Mease, Laura C. Coates, Alexa P. Kollmeier et autres

us, gb, ca, nl (code pays fourni par la source)

S1663 Inhibition of Structural Damage Progression With Guselkumab in Participants With Active Psoriatic Arthritis: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study

Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier et autres

Introduction: Extraintestinal manifestations(EIMs), eg, joint involvement and psoriatic arthritis (PsA), are common in pts with IBD and may be associated with more severe IBD. Guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor, is approved to treat CD, UC, PsA, and psoriasis. No studies …

Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study

Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier et autres

OBJECTIVES: The APEX study evaluated the effects of guselkumab, a fully human, dual-acting monoclonal antibody able to bind CD64 and selectively inhibit the interleukin (IL)-23p19 subunit, on clinical and radiographic outcomes in active psoriatic arthritis (PsA). METHODS: APEX (ongoing, phase 3b, double-blind, …

us, gb, ca, nl (code pays fourni par la source)

Dynamics of relapse in breast cancer

OM Rueda, Stephen‐John Sammut, Shigyoku Chin, Rattandeep Batra et autres

Development of the Malignant Pleural Effusion Model To Investigate Intratumoral Heterogeneity in Lung Cancer.

SS Oh, SK Basak, MS Veena, Guangyu Huang et autres

P-049 Systemic chemokine CCL19 administration reduces tumorburden in a late stage model of spontaneous lung cancer

Sven Hillinger, Shi‐Yi Yang, Mingguo Huang, Rattandeep Batra et autres